Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?
This article was originally published in The Pink Sheet Daily
Executive Summary
The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics.
You may also be interested in...
Pfizer, Merck Execs Share Emerging Markets Strategies - Windhover's Pharmaceutical Strategic Alliances Conference (Part 1 of 2)
NEW YORK - Emerging markets will account for almost half of the global pharmaceutical market growth through 2014, according to IMS Health VP Rob Arnold
Actavis Eyes Acquisitions In The Middle East And Niche Products In The U.S.
Possibly acquiring development expertise in biosimilars from the Swiss firm BioPartners is one of several strategic moves that newly appointed chief executive Claudio Albrecht is now making at the generics company Actavis
GSK’s Strategy in Emerging Markets: Scale, Diversification and Access
Branded products are key to emerging markets, where they tend to have long lifecycles that extend well beyond patent expiration, GlaxoSmithKline's president of emerging markets Abbas Hussain told investors at a Sanford F. Bernstein conference May 6